News & Media

Today, Jutta Schnirring-Mayer joins Orifarm’s Executive Management Group as Chief Business Development & Portfolio Strategy Officer with responsibility for business development and portfolio strategy within niche generics and prescription medicine. With this executive appointment, Orifarm aims to accelerate the company’s position in the generics market in Europe.  Orifarm is already a leading European supplier of generic medicine, particularly in the Nordics. With the appointment of Jutta Schnirring-Mayer as Chief Business Development & Portfolio Strategy Officer (CBDO), effective today, Orifarm is now intensifying its focus on niche generics and prescription medicine to support its goal of expanding its European presence and increasing access to affordable medicine.   “With the appointment of Jutta Schnirring-Mayer, we aim to intensify our focus on generic medicines – a strategic growth area for Orifarm. We see significant potential to strengthen our position in Europe’s generics market, and will do this through strategic portfolio management, acquisitions, in‑licensing, and product development. Our goal is to deliver high-quality medicine at affordable prices to even more patients,” says Mads Fink Eriksen, CEO of Orifarm.  Jutta Schnirring-Mayer, currently based in Germany, brings extensive experience in generic medicines and portfolio strategy. Generic medicines contain the same active ingredient as the original, but often at a lower cost – benefiting patients and society, who can access treatment with the same effect and safety at a lower price.  Bringing more generic medicines to patients in Europe is a task the new executive is very much looking forward to.  “Orifarm has delivered real value for patients through generic medicines over many years, and I have followed the company with great interest. I am therefore thrilled to be part of accelerating this growth. Exciting opportunities lie ahead for Orifarm, and I look forward to working with the company’s talented employees to strengthen our position and expand our presence in Europe,” says Jutta Schnirring-Mayer.  With more than three decades of experience in the generics industry, Jutta Schnirring-Mayer has built exceptionally deep expertise in the field. She most recently held the position of Vice President at HELM Pharmaceuticals GmbH in Hamburg, Germany, and has previously held leadership roles in prominent life‑science companies such as regenold and ratiopharm. Jutta Schnirring-Mayer also holds an MBA and PED from IMD Business School and is a trained pharmacist from the University of Tübingen.   

Orifarm is pleased to announce the appointment of Sébastien Roche to its Board of Directors, effective November 1. Sébastien brings a wealth of expertise from the pharmaceutical and manufacturing industries, bolstering Orifarm’s mission to provide affordable, high-quality medicine to customers across Europe.   Sébastien Roche, currently Group Chief Operations Officer at Straumann Group, joins Orifarm with extensive international pharma experience and a proven track record in executive leadership.   “We are delighted to welcome Sébastien to Orifarm’s Board of Directors. His deep, international experience in the pharmaceutical and manufacturing industries, combined with his proven leadership at executive level, will be a strong asset as we continue to expand access to affordable, high-quality medicines across Europe,” says Hans Bøgh-Sørensen, Owner and Chairman of the Board at Orifarm.   Sébastien Roche expressed his excitement about his new role Orifarm: “I am honored to join Orifarm’s Board of Directors. The company's commitment to improving access to affordable medicine resonates strongly with me. I look forward to leveraging my international experience in pharmaceuticals and manufacturing to support Orifarm’s growth and delivering value for patients and healthcare systems in Europe.”  Strong international pharma profile  Sébastien is currently Executive Vice President, Group Chief Operations Officer, and a Member of the Executive Management Board at Straumann Group, a global leader in oral health.In his role, Roche oversees manufacturing, supply chain, quality, and regulatory affairs across Straumann’s extensive network of 20 sites in Europe, the US, Brazil, China, and Japan. His responsibilities include driving the end-to-end supply chain to provide a strong service to customers, managing manufacturing to deliver high-quality products in the most competitive manner, and ensuring that operations are compliant to constantly deliver safe products for patients.  Before joining Straumann Group in 2022, Sébastien held senior leadership positions at TEVA Pharmaceuticals, where he served as Senior Vice President, overseeing up to 28 manufacturing sites across the US, Latin America, Europe, and Asia.  Sébastien’s international experience is extensive, having worked in over 15 countries and resided in Switzerland, France, Germany, Czech Republic, China, and Croatia. He is 53 years old, married, and currently lives in Switzerland.   Sébastien holds a Master’s degree in Aeronautics and Space from Institut Supérieur de l’Aéronautique et de l’Espace in Toulouse, France.   Orifarm’s Board of Directors  Sébastien’s appointment comes after Anders Hagh decided to step down in May from the Board of Directors to focus on his role as CEO of Salling Group. Orifarm’s Board of Directors now consists of the following members:   Hans Bøgh-Sørensen, Chairman   Ole Michael Friis, Vice Chairman    Adeel Ahmad    Claudio Albrecht    Heidi Wase Skovhus    Jeffrey Martin Rope    Nicola Falcinelli    Sébastien Roche  Bettina Britt Juel Hansen, employee-elected member    Gitte Alhed Poulsen, employee-elected member  Jeanette Jæger Wallentin, employee-elected member. 

After many exceptional years with Orifarm, we bid farewell to Chief Business Development Officer and Executive Management Group member Ulrik Kronborg Markussen, who has decided to leave the company to pursue new challenges. Ulrik’s departure is an opportunity to reflect on his remarkable career and unique legacy.      Ulrik’s career at Orifarm began in 1999 when he was hired by our Founder and Owner, Hans Bøgh-Sørensen. A trained accountant with a good nose for business, Ulrik quickly showcased his strengths and made his mark.    One of Ulrik's most significant contributions was the establishment of Orifarm Generics in 2000. Building the business from the ground up, Ulrik sourced the company’s very first dossiers and oversaw the launch of its first generic products. His vision and persistence laid the foundation for a platform that remains central to Orifarm today.    In 2009, Ulrik left to pursue his entrepreneurial dream, co-owning Growth House — a company that Orifarm later acquired in 2015. Ulrik played a key role in the integration and rejoined Orifarm, once again shaping our growth journey.    Over the years, his strategic insight and exceptional negotiation skills have been pivotal in several transformative acquisitions, including Pharma Westen in Germany and, more recently, the landmark Takeda carve-out. These milestones have been instrumental in realizing our growth ambitions and strengthening Orifarm’s position in the pharmaceutical industry.    A fond farewell     Ulrik’s remarkable contributions were celebrated at a farewell reception at Orifarm headquarters last week. Reflecting on his time with the company, Ulrik shared:    “It’s been a true honour to be part of Orifarm’s growth journey and work alongside so many talented individuals. This company believes in its people from day one, giving them the freedom to dream big and make those dreams a reality. I feel incredibly fortunate to have had so many exciting opportunities over the years, and I want to thank everyone for their collaboration and support. Orifarm will always stay close to my heart, but now it is time for me to seek new challenges.”    We wish Ulrik every success in his next chapter.   

Orifarm announces two new appointments to its Executive Management Group, effective today. Kenneth Svendsen joins as new Chief Information Officer (CIO) and Nicki Lund Kristensen is appointed new Chief Financial Officer (CFO). The move strengthens the executive leadership team, and will support Orifarm in delivering profitable growth and executing on its strategic priorities. “I am excited to welcome Kenneth Svendsen and Nicki Lund Kristensen to Orifarm’s Executive Management Group today. These appointments will play a key role in securing profitable growth, executing on our strategic priorities – delivering on our mission to provide affordable, high-quality healthcare to even more patients, customers and societies across our markets,” says Mads Fink Eriksen, CEO at Orifarm. New CIO to spearhead tech journey   Kenneth Svendsen is an experienced international IT leader with a strong track record in leading digital, business-driven transformations. With his strong focus on supporting strategic development and optimizing IT operations, Kenneth Svendsen will be responsible for building technology resilience and capabilities that deliver value across the business. The appointment marks the expansion of Orifarm’s Executive Management Group. “I’m excited to join Orifarm’s executive management at a time of such momentum. Technology is at the heart of Orifarm’s growth journey, shaping everything from operations to strategy. I look forward to accelerating this journey by harnessing the potential of technologies and AI across our value chain. By supporting our strategic priorities, optimizing operations and making future-proof tech investments, I will be strongly focused on driving value in all parts of the business,” says Kenneth Svendsen, CIO at Orifarm. Kenneth Svendsen has held several international leadership positions, most recently CIO at Dagrofa. Prior to this Kenneth Svendsen was Division CIO at DSV, Group CIO at FLSmidth and CTO at Saint-Gobain General Delegation Nordic & Baltic. He holds a bachelor in Computer Science from Niels Brock Copenhagen Business College. Kenneth Svendsen is 51 years old, married and has three children. New CFO to continue growth trajectory As Orifarm’s new CFO, Nicki Lund Kristensen will play an even more instrumental role in steering Orifarm on its growth trajectory. Nicki Lund Kristensen has been at Orifarm for more than four years, and has played a key role in financial management in his previous position as Vice President Group Accounting, Compliance and Treasury. His appointment marks the completion of a comprehensive internal and external search following the appointment of Mads Fink Eriksen as CEO. “My primary objective is to build on the strong foundation already in place, made possible by the continued dedication of our employees. Orifarm is delivering robust commercial performance, and as we pursue our long-term growth ambitions, our focus remains on increasing profitability, enhancing scalability, and creating value across the whole value chain,” says Nicki Lund Kristensen, CFO at Orifarm. Prior to joining Orifarm, Nicki Lund Kristensen held various leadership roles at Blue Water Shipping including Head of Treasury. He holds a Graduate Diploma in Business Administration (Financial and Management Accounting) from the University of Southern Denmark. The 42-year-old lives in Esbjerg and is the proud parent of two children.   Nicki Lund Kristensen (left) and Kenneth Svendsen (right)  

Thirty years ago, a couple and their dog sat in an office in Odense. They had a filing cabinet, an idea, and an ambition: to make medicine a better deal—not just for themselves, but also for patients and society. This vision sparked a remarkable growth journey, where acquisitions and sales transformed the idea into a European leader in parallel import. Today, Orifarm celebrates its 30th anniversary, and the couple behind this Danish business success story express their gratitude to employees and partners for their support throughout the journey.  On Thursday, May 22, 2025, Orifarm marks its 30th anniversary and an extraordinary growth journey that has made the family-owned Danish company the largest supplier of medicine to Danish pharmacies and Europe’s largest parallel importer of pharmaceuticals.  Behind this journey stands the couple Birgitte and Hans Bøgh-Sørensen, who are still active in the company’s leadership. For the first time, with input from employees and partners, they tell Orifarm’s complete story in the book “Success on Prescription”, published today by Politikens Forlag.  From filing cabinet to multi-billion enterprise Orifarm was founded on the principle of parallel import—buying original medicine at a lower price in one EU country and selling it at a lower cost than the original producer in another.  “We started Orifarm with an idea and a filing cabinet we bought, containing a few documents about products and suppliers. Today, we have an international company and around 2,300 colleagues. We never imagined this back then,” says Hans Bøgh-Sørensen, founder, co-owner, and Chairman of the Board.  An idea with social impact Since then, Orifarm has expanded its business with generic medicine, over-the-counter drugs, vitamins, and dietary supplements — always with a focus on providing cheaper, high-quality pharmaceuticals.  Parallel import alone saved Denmark 740 million DKK in 2021, according to a report by Copenhagen Economics in 20221. Additional savings stem from the generic medicine market, where competition among suppliers has led to lower prices2.  “It’s not just about running a good business—it’s about making a difference. We have always been driven by the desire to create value for both patients and society,” says Hans Bøgh-Sørensen.  A value-based growth company  Orifarm has experienced continuous growth over the years — but not without challenges. Legal hurdles, Brexit, regulatory changes, and other obstacles have caused difficulties but have also often served as a driving force. The company has carried out several strategic acquisitions, most recently acquiring 110 products and two production facilities from the Japanese pharmaceutical giant Takeda in 2020 — Orifarm’s largest and most complex acquisition to date.  “We have never been afraid to think big. But we’ve always put our values first and built on a strong culture. It’s important that we can see ourselves in what we do — even as we grow. Our culture and values are our compass,” says Birgitte Bøgh-Sørensen.  A family-owned business focused on long-term growth Orifarm remains 100% family-owned. Today, the company is owned by the couple’s three adult children — Christian, Anne-Charlotte, and Andreas — who each own 30%. Hans Bøgh-Sørensen holds the remaining 10% and the controlling shares, ensuring continuity as the next generation prepares to carry forward what their parents built.  “But Orifarm is not just our story — it has been created by many. We owe a deep gratitude to everyone who has been part of it — whether in administration, production, or behind the scenes. We are incredibly thankful to them,” says Hans Bøgh-Sørensen.  Orifarm achieved record revenue of approximately 13.5 billion DKK last year (2024) and now poised for a new growth phase, aiming to significantly expand its business establish itself as a mid-sized European pharmaceutical leader, starting in Northern Europe and expanding across the continent. “We have Europe’s strongest position in parallel import and a solid foundation in generic medicine. Now, we want to use this as a springboard for something even bigger. Our ambitions remain unchanged — we are just getting started,” says Hans Bøgh-Sørensen.          ------------------------------ Book release: On Thursday, May 22, 2025, the book Success on Prescription – The Story of Orifarm will be published by Politikens Forlag. Released in celebration of Orifarm’s 30th anniversary, the book is written by journalist Tom Okke. Based on interviews with Birgitte and Hans Bøgh-Sørensen, along with more than 20 former and current employees and partners, the author portrays the company's transformation over the past 30 years.  Sources:  1.    Copenhagen Economics: The Impact of Parallel Imported Medicine (Copenhagen Economics: Effekten af parallel importeret medicin)2.    IGL: Societal Savings from Generic Medicines (IGL: Besparelser til samfundet med generika) Image material: Portrait photo of Birgitte and Hans Bøgh-Sørensen. Photographer must be credited when used: Jens Peter Engedal.  

Orifarm announced today the appointment of Mads Fink Eriksen as CEO with immediate effect. Mads, who has been serving as CFO and interim CEO, is poised to propel the company forward on its growth trajectory by expanding its commercial platform and delivering sustainable, profitable growth.   The appointment by the Board of Directors follows a comprehensive search process with support from international advisers and a detailed evaluation of internal and external candidates.   Hans Bøgh-Sørensen, Owner and Chairman of the Board, said: “The Board is delighted to appoint Mads Fink Eriksen as Orifarm’s new CEO. Having undertaken a thorough screening process involving high-caliber candidates, the Board unanimously agrees that Mads is the right leader for Orifarm. His strong leadership qualities, proven ability to execute and embodiment of Orifarm’s values make Mads the right match to steer Orifarm on the next phase of our growth journey. We look forward to working with Mads as we move towards an even stronger future.”  Mads brings many years of leadership in growing international companies, latterly from the family-owned company ECCO. His experience spans the entire value chain, with roles in production, sales, and corporate functions. Throughout his career, his strong business acumen and leadership skills have consistently driven solid financial results and strategic transformation. As CEO, Mads will focus on continuing Orifarm’s strong growth journey by expanding the company’s commercial platform and delivering sustainable growth. Mads Fink Eriksen expressed his commitment to the role: “I am honored to lead Orifarm – an ambitious company with great people. To realize our many opportunities ahead, our focus remains on strengthening our foundation for sustainable, profitable growth. As we continue expanding our portfolio and global footprint, my task is to improve profitability, build a more scalable organization and execute on our strategic priorities. Together with the executive management group and the Board, I look forward to building on Orifarm’s impressive legacy so we can provide access to high-quality, affordable medicine to even more customers in the future.” Mads joined Orifarm in October last year and has been interim CEO since the end of March. Orifarm will now start the search for a new CFO.   About Mads Fink Eriksen Before joining Orifarm, Mads Fink Eriksen spent 14 years with ECCO, starting in China, followed by several years in Singapore in ECCO’s Global Production Headquarter. He then spent three years at ECCO’s headquarters in Denmark as Head of Corporate Finance. In 2018, he moved to Australia, where he successfully restructured ECCO’s sales organization in Oceania. In 2020, he was appointed Chief Financial Officer for the ECCO Group. Mads holds an Executive MBA from the renowned INSEAD Business School. Mads, 42, is married with two children. 

Danish pharmaceutical company Orifarm delivered solid results in 2024, achieving 16% revenue growth and the highest turnover in the company’s history. Despite robust commercial performance, higher operational costs resulted in a decline in operating profit. To lead the business through the next phase of its growth journey, Orifarm has announced the search for a new CEO. Orifarm delivered solid results in 2024, generating robust commercial performance and improving cash flow. Revenue grew 16% reaching a record €1.816bn, fuelled primarily by 19% growth in the Pharma Trade segment and 9% growth in Specialty Rx. Additionally, free cash flow improved to €40.6m (2023: -€10.5m), driven by stronger working capital management. In 2024, Orifarm reinforced its financial position through a new financing partnership with Carlyle and the refinancing of senior facilities with Danske Bank, Nykredit, and Jyske Bank. However, higher operating costs resulted in an operating profit of €69.4m, a 9% decline from the previous year. To address this, Orifarm has taken steps to build a scalable organisation positioned for sustainable growth. These measures included workforce adjustments at the beginning of 2025 and plans to nearshore up to approximately 140 positions to Warsaw, Poland by the end of 2026. "Orifarm is pleased with our record revenue growth and cash flow improvements thanks to the continuous dedication from our employees. To fulfil our long-term growth ambitions, we also need to build a more scalable organisation and control costs. As we continue expanding our portfolio and global footprint, our focus in 2025 will be on improving profitability, so we can provide affordable high-quality medicine to even more consumers across Europe," says Mads Fink Eriksen, CFO at Orifarm. This year, the company anticipates 5% revenue growth and aims to increase operating profit by 5–10%. Orifarm’s strategic priorities for 2025 include plans to enter the Spanish market, launch speciality Rx in Germany and continue to pursue merger and acquisitions.   Orifarm to find new CEO To lead the company in the next phase of its growth journey, Orifarm’s Board of Directors has decided to find a new CEO. The Board would like to express its gratitude to Erik Sandberg, who steps down as CEO with immediate effect. Orifarm’s CFO Mads Fink Eriksen will act as interim CEO until a new CEO is appointed. Commenting on the decision, Hans Bøgh-Sørensen, Owner and Chairman of the Board, says: “Orifarm’s Board of Directors has decided to find a new CEO to guide the company through the next stage of its growth journey. We would like to thank Erik Sandberg for his substantial and loyal contribution to Orifarm over the past 13 years, in which he has significantly strengthened the company’s position by expanding the company’s portfolio and global footprint. The Board will now start the search for a new CEO and during this time Mads Fink Eriksen will act as interim CEO.” Erik Sandberg says: “It has been a privilege to lead Orifarm. I am proud to have led the company through a strategic transformation over the past 13 years and would like to thank Orifarm’s employees for their dedication and support. I respect the Board’s decision to find a new CEO for the next part of Orifarm’s journey and look forward to seeing the company continuing to grow in the future.” In addition to the CEO leadership changes announced today, the Board has appointed Thomas Brandhof, Chief Commercial Officer at Orifarm, to join Mads Fink Eriksen on the executive board. 2024 financial highlights  Revenue grew 16% reaching €1.816bn, the highest turnover in the company’s history.  Product portfolio delivered strong commercial performance fuelled by 19% growth in the Pharma Trade segment and 9% growth in Specialty Rx. Higher operating costs resulted in an operating profit of €69.4m, a 9% decline from the previous year. Cash flow improved to €40.6m (2023: -€10.5m), driven by stronger working capital management.

Orifarm Group A/S ("Orifarm"), is pleased to announce that the strategic investment with Carlyle Global Credit (NASDAQ: CG) has successfully closed following approval from relevant regulatory authorities. Orifarm is a dynamic, family-owned, international healthcare company, supplying high quality pharmaceuticals at affordable prices through a unique commercial platform covering three business areas: Pharma Trade, Specialty Rx and Consumer Healthcare. This strategic investment, as announced on 13 September 2024, will look to strengthen Orifarm’s ongoing expansion, both organic and inorganic, building on its strong pan-European presence, and expand its coverage of accessible, high-quality, and affordable medicines. "This capital infusion will significantly enhance our ability to capitalize on the attractive opportunities, both organic and inorganic, that we have positioned Orifarm for. We are delighted to have Carlyle as a strategic capital partner to support this next chapter of Orifarm’s growth,” said Erik Sandberg, CEO of Orifarm Group. Orifarm was founded in 1994 by Hans and Birgitte Bøgh-Sørensen and will remain privately owned by the family following this transaction. The terms of the transaction are confidential. Rothschild & Co acted as the sole financial advisor to Orifarm and owners, Habico, together with the owners’ dedicated family office, Habico Invest. Kromann Reumert was legal advisor to Orifarm and Habico.   Related news: 13 September 2024: Orifarm Group Announces Strategic Investment from Carlyle Global Credit   About Orifarm Group A/SOrifarm is a dynamic family-owned international healthcare company supplying high-quality pharmaceuticals at affordable prices through a unique commercial platform covering three business areas: Pharma Trade, Specialty Rx, and Consumer Healthcare. Headquartered in Odense, Denmark, Orifarm is Europe's largest parallel importer of pharmaceuticals and Denmark's largest supplier of pharmaceuticals, with 2,300 employees in 16 countries and an annual turnover of more than €1.5 billion (2023).   About Carlyle Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $435 billion of assets under management as of June 30, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,200 people in 29 offices across four continents. Further information is available at www.carlyle.com.   For further information, please contact: Kristian Lysgaard, VP of Communications, Orifarm Group A/SEmail: krlys@orifarm.comPhone: +45 25 56 85 61

The official inauguration of the new office for Orifarm's Swedish subsidiary, located in the heart of Stockholm, was celebrated with a memorable event. The afternoon featured the presence of prominent visitors, which beyond the owners Birgitte and Hans Bøgh-Sørensen, CEO Erik Sandberg, CPO Andreas Friis, and CFO Mads Find Eriksen. The highlight of the event was the official ribbon-cutting ceremony, performed by Birgitte Bøgh-Sørensen, who played a significant role in the office's design. The celebration included toasts with sparkling beverages and a selection of macaroons and cupcakes in Orifarm's colors.General Manager of Orifarm Sweden Christian Vallentin and his team presented the latest success stories from Sweden, followed by a celebration of an all-time high in October sales, marking a significant achievement for the Swedish team. Perfect timing to celebrate at the inauguration!  CEO Erik Sandberg delivered an inspiring speech to the team, and Owner and Chairman Hans Bøgh-Sørensen provided a historical overview of the Swedish business from its inception to the present day. The speeches and presentations were well-received by all attendees. “It was really a joyful celebration and at the same time inspiring event with Hans and Birgitte, and several EMG members visiting us at the same time. We have really accomplished new huge milestones for Orifarm SE last years, with profitable growth in all business areas and a more mature local organization that is truly based on 3 business platforms. We are also indeed very excited and pleased to have move into our new Orifarm themed modern and more spacious office in really the center of Stockholm, where we look forward to host many more important events.” says Christian Vallentin.       The event marked a significant milestone for Orifarm in Sweden, setting the stage for continued success in the new office space.